Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Zoe E C Hopkinson a University Department of Obstetrics and
Gynaecology, Glasgow Royal Infirmary University NHS Trust,
Glasgow G31 2ER, b University Department of Clinical Biochemistry, Glasgow
Royal Infirmary University NHS Trust
Correspondence to: Dr Hopkinson
z.hopkinson@clinmed.gla.ac.uk
| The first 150 words of the full text of this article appear below. |
Polycystic ovarian syndrome is the most common form
of anovulatory infertility.1 Its association with
menstrual disturbance and altered hormonal parameters leads many
affected women of reproductive age to attend a gynaecology or
infertility clinic. The aetiology of the condition is unknown, but
recent evidence suggests that the principal underlying disorder is one
of insulin resistance, with the resultant hyperinsulinaemia stimulating
excess ovarian androgen production. Associated with the prevalent
insulin resistance, these women exhibit a characteristic dyslipidaemia
and a predisposition to non-insulin dependent diabetes and
cardiovascular disease in later life. Thus, polycystic ovarian syndrome
seems to have many of the hallmarks of the metabolic
syndrome.2-4 This article focuses on the recent change in
attitudes to polycystic ovarian syndrome arising from the link with
insulin resistance
a concept that not only has major implications for
the health of affected women but also offers a potential for new
treatments.
| Table Removed (Available Only in the Full Text) |
| |
Methods |
|---|
This article is derived
Read all Rapid Responses